SET Protein in Cancer: A Potential Therapeutic Target

Mini Rev Med Chem. 2021;21(16):2290-2299. doi: 10.2174/1389557521666210114163318.

Abstract

SET protein is a multi-functional oncoprotein that is ubiquitously expressed in most tumor cells. Dysregulation of SET has been associated with many types of cancer. Due to ever-accumulating evidence of its strong correlation with both poor prognosis and drug resistance, the targeting of SET is starting to be explored. SET is currently regarded as a potential target for cancer therapy, and several inhibitors are being developed for clinical trials. In this review, the physiological and pathological functions of SET, as well as its antagonists, will be discussed along with the prospects and challenges involved with translating SET inhibitors into bona fide therapeutic options.

Keywords: SET; cancer; dysregulation; inhibitors.; oncoprotein; prognosis; resistance.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • DNA-Binding Proteins / antagonists & inhibitors*
  • DNA-Binding Proteins / metabolism*
  • Histone Chaperones / antagonists & inhibitors*
  • Histone Chaperones / metabolism*
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • DNA-Binding Proteins
  • Histone Chaperones
  • SET protein, human